Компания XM не предоставляет услуги резидентам Соединенных штатов Америки.
A
A

Agilent


Новости

Italy to March 31

DIARY - Italy to March 31 Inclusion of diary items does not necessarily mean that Reuters will file a story based on the event. THURSDAY FEBRUARY 22 ISTAT releases January CPI final data (0900 GMT). Treasury announces sale of 6-month BOT bills, with relative amounts to be auctioned on Feb. 27. Rome, Senate holds question time session with Industry Minister Adolfo Urso (1400 GMT).
A
A
B
E
E
I
M
P
R
S
S
S
T
U
U
V
A
A
A
B
B
D
D
F
I
P
P
U

Medical equipment makers slide after Thermo Fisher's downbeat 2024 forecasts

BUZZ-Medical equipment makers slide after Thermo Fisher's downbeat 2024 forecasts ** Shares of some medical equipment makers down after Thermo Fisher Scientific TMO.N forecasts downbeat 2024 and remains cautious on biotech demand recovery ** TMO's 2024 forecasts signal a continued slump in demand for its services used to make therapeutics and vacci
A
T

Thermo Fisher forecasts 2024 below estimates, cautious on biotech demand

UPDATE 5-Thermo Fisher forecasts 2024 below estimates, cautious on biotech demand Updates shares in paragraph 2 By Bhanvi Satija Jan 31 (Reuters) - Thermo Fisher Scientific TMO.N on Wednesday forecast annual profit and revenue below Wall Street estimates, signaling that a slump in demand for its services used to make therapies and vaccines will extend at least into the first half of the year.
A
T

Agilent Announces Collaboration With Incyte

BRIEF-Agilent Announces Collaboration With Incyte Jan 30 (Reuters) - Agilent Technologies Inc A.N : AGILENT ANNOUNCES COLLABORATION WITH INCYTE TO DEVELOP ADVANCED COMPANION DIAGNOSTICS IN HEMATOLOGY AND ONCOLOGY Source text for Eikon: ID:nBwsXMKma Further company coverage: A.N
A

Danaher forecasts revenue decline in 2024, shares fall

Danaher forecasts revenue decline in 2024, shares fall Jan 30 (Reuters) - Life sciences firm Danaher DHR.N forecast a low single-digit percentage decline year-over-year in its 2024 adjusted core revenue on Tuesday, sending the shares down nearly 4% before the bell. Life sciences companies such as Danaher, Agilent A.N and Thermo Fisher TMO.N had cut their sales forecasts last year on slowing growth in China paired with a funding crunch in biotech.
A
T

U.S. Beam Therapeutics, Lam Research, Vir Biotechnology

U.S. RESEARCH ROUNDUP-Beam Therapeutics, Lam Research, Vir Biotechnology Jan 29 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Beam Therapeutics, Lam Research and Vir Biotechnology, on Monday. HIGHLIGHTS * Beam Therapeutics Inc BEAM.O : JP Morgan raises to overweight from neutral * C4 Therapeutics Inc CCCC.O : JP Morgan raises to neutral from underweight * Lam Research Corp LRCX.O : Susquehanna raises target price t
A
A
B
C
D
F
A
A
D
E
L
D
I
L
A
A

U.S. Amazon.com, Equifax, Tesla

U.S. RESEARCH ROUNDUP-Amazon.com, Equifax, Tesla Jan 25 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Amazon.com, Equifax and Tesla, on Thursday. HIGHLIGHTS * Amazon.com Inc AMZN.O : Jefferies raises price target to $190 from $175 * Columbia Banking System Inc COLB.O : KBW cuts to market perform from outperform * Equifax Inc EFX.N : National Bank of Canada raises to outperform from sector perform * ServiceNow Inc N
A
A
A
A
A
A
B
C
C
C
C
G
G
I
T
A
F
B
A
A
A
B
E

U.S. DXC Technology, Figs, Maplebear

U.S. RESEARCH ROUNDUP-DXC Technology, Figs, Maplebear Jan 24 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including DXC Technology, Figs and Maplebear, on Wednesday. HIGHLIGHTS * DXC Technology Co DXC.N : JP Morgan cuts to underweight from neutral * Figs Inc FIGS.N : Barclays raises to equal weight from underweight * Maplebear Inc CART.O : Benchmark cuts to hold * Vertex Pharmaceuticals Inc VRTX.O : Canaccord Genuity cuts t
A
A
A
A
A
B
G
H
M
N
P
H
M
A
B

Italy - Factors to watch on Jan. 22

Italy - Factors to watch on Jan. 22 The following factors could affect Italian markets on Monday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy. New items are marked with (*). For a complete list of diary events in Italy please click on IT/DIA . POLITICS In a meeting on Saturday, Italian Prime Minister Giorgia Meloni and Turkey's President Tayyip Erdogan discussed a memorandum of understanding on migration that could be soon signed to reduce migrant departur
A
A
B
E
I
L
M
M
S
U
U
A
J
M
P
I
U

EU December car sales down 3.3% y/y as German market slows -ACEA

EU December car sales down 3.3% y/y as German market slows -ACEA By Alessandro Parodi and Greta Rosen Fondahn Jan 18 (Reuters) - New car sales in the European Union declined by 3.3% in December, dragged down by slowing demand in Germany, data showed on Thursday, in the first decrease in 16 months. The year-on-year drop can also be attributed to a comparatively strong performance of the market in December 2022, the European Automobile Manufacturers Association (ACEA) said.
A
P
R
T
V

U.S. Agilon Health, Dell Technologies, Fabrinet

U.S. RESEARCH ROUNDUP-Agilon Health, Dell Technologies, Fabrinet Jan 8 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Agilon Health, Dell Technologies and Fabrinet on Monday. HIGHLIGHTS * Agilon Health Inc AGL.N : RBC cuts target price to $11 from $23 * Brown & Brown Inc BRO.N : RBC raises to outperform from sector perform * Dell Technologies Inc DELL.N : JP Morgan raises to overweight from neutral * Fabrinet FN.N :
A
A
C
C
E
E
E
A
U
F
F
G
A
A
A

Agilent Makes Strategic Updates To Organizational Structure

BRIEF-Agilent Makes Strategic Updates To Organizational Structure Dec 20 (Reuters) - Agilent Technologies Inc A.N : AGILENT MAKES STRATEGIC UPDATES TO ORGANIZATIONAL STRUCTURE AGILENT TECHNOLOGIES INC- MOVED COMPANY'S CELL ANALYSIS DIVISION INTO ITS DIAGNOSTICS AND GENOMICS GROUP (DGG) AGILENT TECHNOLOGIES INC - AGILENT WILL REPORT UNDER THIS NEW S
A

U.S. Adobe, Oracle, Visa

U.S. RESEARCH ROUNDUP-Adobe, Oracle, Visa Dec 12 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Adobe, Oracle and Visa, on Tuesday. HIGHLIGHTS * Adobe Inc ADBE.O : JP Morgan raises target price to $600 from $530 * Costco Wholesale Corp COST.O : Evercore ISI raises target price to $650 from $640 * Martin Marietta Materials Inc MLM.N : JP Morgan raises to overweight from neutral * Oracle Corp ORCL.N : Barclays cuts ta
A
A
A
A
A
A
C
C
E
S
V
V
A
A
A
A
D
M

U.S. stocks weekly: Fourth helping

RPT-BUZZ-U.S. stocks weekly: Fourth helping Repeats from Friday with no changes to text, updates chart ** S&P 500 .SPX adds 1%, now up 4 weeks in a row .N ** Nasdaq .IXIC and DJI .DJI have also scored 4-straight weeks of gains ** This, with the U.S. 10-year Treasury yield's US10YT=RR monthly win streak in jeopardy ** SPX recent rally, biggest in more than 3 years as the Magnificent Seven still laying down the law ** Every sector goes back for more: healthcare, staples most stuffed ** Healthcare
A
B
M
N
U
U
U

S&P 500 top and bottom performing stocks at about 03:30 p.m. EST

BUZZ - S&P 500 top and bottom performing stocks at about 03:30 p.m. EST S&P 500 .SPX Top Performers Percent Change CF Industries Holdings Inc CF.N +2.6% Best Buy Co Inc BBY.N +2.2% Agilent Technologies Inc A.N +2.1% WestRock Co WRK.N +2.1% Fidelity National Information Services Inc FIS.N +2.0% Bottom Performers Percent Change First Solar Inc FSLR.O
A
G
N
U
F
W

U.S. stocks weekly: Fourth helping

BUZZ-U.S. stocks weekly: Fourth helping ** S&P 500 .SPX adds 1%, now up 4 weeks in a row .N ** Nasdaq .IXIC and DJI .DJI have also scored 4-straight weeks of gains ** This, with the U.S. 10-year Treasury yield's US10YT=RR monthly win streak in jeopardy ** SPX recent rally, biggest in more than 3 years as the Magnificent Seven still laying down the law ** Every sector goes back for more: healthcare, staples most stuffed ** Healthcare .SPXHC up 2.2%.
A
B
M
N
U
U
U

U.S. Clorox, GoDaddy, Reynolds Consumer Products

U.S. RESEARCH ROUNDUP-Clorox, GoDaddy, Reynolds Consumer Products Nov 22 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Clorox, GoDaddy, and Reynolds Consumer Products, on Wednesday. HIGHLIGHTS * Clorox Co CLX.N : JP Morgan raises to neutral from underweight * Equinix Inc EQIX.O : Citigroup raises price target to $895 from $830 * GoDaddy Inc GDDY.N : RBC raises to outperform from sector perform * Guess Inc GES.N : J
A
A
B
C
N
U
A
C
J
K

S&P 500 top and bottom performing stocks at about 12:00 p.m. EST

BUZZ - S&P 500 top and bottom performing stocks at about 12:00 p.m. EST S&P 500 .SPX Top Performers Percent Change Agilent Technologies Inc A.N +8.9% Mettler-Toledo International Inc MTD.N +6.7% Waters Corp WAT.N +6.3% Danaher Corp DHR.N +4.5% Thermo Fisher Scientific Inc TMO.N +4.3% Bottom Performers Percent Change Jacobs Solutions Inc J.N -8.1% V
A
C
U
T
W
J
L
M

U.S. STOCKS Dycom Industries, Crypto stocks, Burlington Stores

BUZZ-U.S. STOCKS ON THE MOVE-Dycom Industries, Crypto stocks, Burlington Stores Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stocks fell on Tuesday as investors awaited Nvidia's quarterly results and the Federal Reserve's policy meeting minutes, while multiple downbeat earnings from retailers also weighed on sentiment.
A
B
C
C
C
N
Z
U
U
U
W
X
C
M

Agilent rises as Q4 beat outweighs weak 2024 forecast

BUZZ-Agilent rises as Q4 beat outweighs weak 2024 forecast ** Shares of medical equipment maker Agilent Technologies A.N up 6.7% at $121.6 premarket ** Co posts Q4 adj. profit/share of $1.38 vs analysts' estimates of $1.34, thanks to lower costs ** Reports Q4 rev of $1.69 bln, vs estimates of $1.67 bln - LSEG data ** Lower costs and sequential impr
A
J



Условия

Попул. активы

Правовая оговорка: Компании группы XM Group предоставляют только услуги по исполнению сделок и доступ к нашей торговой онлайн-среде, в которой пользователи могут просматривать и (или) пользоваться материалами, доступными на вебсайте либо доступными по ссылкам с данного сайта на другие. Предоставление доступа к онлайн-среде не меняет сути предоставляемых услуг и не расширяет их. Такой доступ и пользование материалами предоставляются с учетом:(i) «Условий и положений»; (ii) «Предупреждений о рисках» и (iii) полного текста «Правовой оговорки». Следовательно, подобные материалы предоставляются лишь в качестве информации общего характера. В частности, просим Вас иметь в виду, что материалы, содержащиеся в нашей торговой онлайн-среде, не являются ни просьбой осуществить какие-либо транзакции на финансовых рынках, ни предложением к осуществлению подобных транзакций. Торговля на любом финансовом рынке подразумевает большой риск потери Вашего капитала.

Все материалы, опубликованные в нашей торговой среде, предоставляются только в образовательных или информационных целях и не содержат (и не должны рассматриваться как содержащие) финансовых, инвестиционных или торговых рекомендаций, а также информации о стоимости наших услуг по предоставлению доступа к рынкам, либо предложения или содействия в проведении транзакций по какому-либо финансовому инструменту или по незапрашиваемым финансовым услугам по отношению к Вам.

Любые материалы на данном вебсайте, созданные третьими лицами, а также материалы, подготовленные XM, такие как мнения экспертов, новости, исследования, анализ, котировки и другая информация, а также ссылки на сторонние сайты предоставляются в виде «как есть», как рыночная информация общего характера, и не являют собой рекомендации по инвестициям. Принимая во внимание то, что любые материалы рассматриваются как инвестиционное исследование, Вам следует учесть и принять тот факт, что никакие материалы не подготавливались и не предназначались к использованию в соответствии с правовыми нормами, способствующими независимости инвестиционных исследований. Следовательно, материалы следует рассматривать как материалы рекламного характера согласно соответствующим законам и правовым нормам. Рекомендуем Вам прочесть и уяснить для себя положения наших «Уведомления о субъективном инвестиционном исследовании» и «Предупреждения о рисках» в отношении приведённой выше информации. С этими документами можно ознакомиться здесь.